{"id":3495,"date":"2026-06-03T06:40:37","date_gmt":"2026-06-03T06:40:37","guid":{"rendered":"https:\/\/tansan.com.tr\/?p=3495"},"modified":"2026-06-03T06:43:25","modified_gmt":"2026-06-03T06:43:25","slug":"kanser-tedavisinde-yeni-gelismeler","status":"publish","type":"post","link":"https:\/\/staging.tansan.com.tr\/en\/kanser-tedavisinde-yeni-gelismeler\/","title":{"rendered":"New Developments in Cancer Treatment"},"content":{"rendered":"

\u00b7 Chicago, ABD’de d\u00fczenlenen 2026 ASCO Y\u0131ll\u0131k Toplant\u0131s\u0131 temel al\u0131narak haz\u0131rlanm\u0131\u015ft\u0131r \u00b7<\/p>\n

\n
\n
\n

D\u00fcnyan\u0131n en b\u00fcy\u00fck kanser kongresinden hastalar i\u00e7in sade bir \u00f6zet<\/p>\n

    \n
  • Tansan Klini\u011fi<\/li>\n
  • Haziran 2026<\/li>\n
  • 450+ bilimsel \u00e7al\u0131\u015fma<\/li>\n<\/ul>\n<\/div>\n<\/div>\n
    \n

    Her y\u0131l may\u0131s\u2013haziran aylar\u0131nda, d\u00fcnyan\u0131n d\u00f6rt bir yan\u0131ndan kanser uzmanlar\u0131 ASCO Y\u0131ll\u0131k Toplant\u0131s\u0131<\/strong>‘nda bir araya gelir. Bu toplant\u0131, kanser tedavisindeki en \u00f6nemli yeniliklerin ilk kez duyuruldu\u011fu yerdir. 2026 toplant\u0131s\u0131na 40.000’den fazla uzman<\/strong> kat\u0131ld\u0131. A\u015fa\u011f\u0131da en dikkat \u00e7ekici ve hastalar i\u00e7in en umut verici sonu\u00e7lar\u0131, t\u0131p e\u011fitimi olmayan ki\u015filerin de anlayabilece\u011fi bir dille \u00f6zetledik.<\/p>\n<\/div>\n

    \n
    \n

    Pankreas Kanseri<\/span> \u2014 Ya\u015fam s\u00fcresini neredeyse iki kat\u0131na \u00e7\u0131kard\u0131<\/h2>\n<\/div>\n
    \n

    Pankreas kanseri, tedavisi en zor kanserlerden biridir ve y\u0131llard\u0131r bu alanda b\u00fcy\u00fck bir ilerleme ya\u015fanmam\u0131\u015ft\u0131. Bu nedenle daraxonrasib<\/strong> adl\u0131 yeni bir ilac\u0131n sonu\u00e7lar\u0131 toplant\u0131n\u0131n en \u00e7ok konu\u015fulan haberi oldu. Bu ila\u00e7, kanser h\u00fccrelerinin b\u00fcy\u00fcmesine yol a\u00e7an RAS<\/em> adl\u0131 bir proteini hedef alan, a\u011f\u0131zdan al\u0131nan bir hap<\/strong>t\u0131r.<\/p>\n

    \n
    \n
    6,7 ay – Eski tedaviyle ortalama ya\u015fam s\u00fcresi<\/div>\n<\/div>\n
    \n
    13,2 ay – Daraxonrasib ile ortalama ya\u015fam s\u00fcresi<\/div>\n<\/div>\n<\/div>\n

    RASolute 302 \u00e7al\u0131\u015fmas\u0131nda ila\u00e7 ayr\u0131ca kemoterapiye g\u00f6re daha az ciddi yan etki olu\u015fturdu.<\/p>\n

    \n
    Bu ne anlama geliyor?<\/strong><\/div>\n

    Uzun y\u0131llard\u0131r se\u00e7eneklerin \u00e7ok k\u0131s\u0131tl\u0131 oldu\u011fu bu kanser t\u00fcr\u00fcnde, hem daha uzun ya\u015fam hem de daha iyi ya\u015fam kalitesi sunan, i\u011fne yerine hap \u015feklinde al\u0131nabilen yeni bir tedavi ufukta g\u00f6r\u00fcn\u00fcyor. \u0130lac\u0131n onay s\u00fcreci ba\u015flam\u0131\u015ft\u0131r.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

    \n
    \n

    Prostat Kanseri <\/span>\u2014 Ameliyatla birlikte yay\u0131lma riskini azaltt\u0131<\/h2>\n<\/div>\n
    \n

    Y\u00fcksek riskli ama hen\u00fcz yay\u0131lmam\u0131\u015f prostat kanserinde, hastalar genellikle ameliyat olur; ancak yakla\u015f\u0131k yar\u0131s\u0131nda kanser zamanla geri d\u00f6ner. PROTEUS \u00e7al\u0131\u015fmas\u0131<\/strong>, ameliyattan \u00f6nce ve sonra hormon tedavisine apalutamide<\/strong> adl\u0131 bir hap eklemenin sonu\u00e7lar\u0131n\u0131 inceledi.<\/p>\n

    \n
    \n
    %20 Yay\u0131lma veya \u00f6l\u00fcm riskinde azalma<\/div>\n<\/div>\n
    \n
    9\u00d7 Ameliyatta t\u00fcm\u00f6r\u00fcn tam yok olma ihtimali<\/div>\n
    <\/div>\n<\/div>\n<\/div>\n
    \n
    Bu ne anlama geliyor?<\/strong><\/div>\n

    Erken evre y\u00fcksek riskli prostat kanserinde, ameliyat\u0131 g\u00fc\u00e7l\u00fc bir ila\u00e7la desteklemek hastal\u0131\u011f\u0131n geri d\u00f6n\u00fc\u015f\u00fcn\u00fc geciktirebilir. Bu yakla\u015f\u0131m, on y\u0131llard\u0131r de\u011fi\u015fmeyen bir tedavi anlay\u0131\u015f\u0131n\u0131 de\u011fi\u015ftirebilecek nitelikte de\u011ferlendiriliyor.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

    \n
    \n

    Ba\u011f\u0131rsak Kanseri \u00b7 BRAF<\/span> \u2014 Ya\u015fam s\u00fcresi iki kat\u0131na \u00e7\u0131kt\u0131<\/h2>\n<\/div>\n
    \n

    Ba\u011f\u0131rsak kanserlerinin k\u00fc\u00e7\u00fck bir k\u0131sm\u0131nda BRAF V600E<\/em> adl\u0131 bir gen de\u011fi\u015fikli\u011fi bulunur ve bu hastalar\u0131n seyri genellikle daha zordur. BREAKWATER \u00e7al\u0131\u015fmas\u0131<\/strong>, standart kemoterapiye enkorafenib + setuksimab<\/strong> adl\u0131 hedefe y\u00f6nelik ila\u00e7lar\u0131n eklenmesini test etti.<\/p>\n

    \n
    \n
    15,1 ay<\/div>\n
    Standart tedaviyle ortalama ya\u015fam s\u00fcresi<\/div>\n<\/div>\n
    \n
    30,3 ay<\/div>\n
    Yeni kombinasyonla ortalama ya\u015fam s\u00fcresi<\/div>\n<\/div>\n<\/div>\n

    \u00d6l\u00fcm riskinde yakla\u015f\u0131k yar\u0131 yar\u0131ya azalma ya\u015fand\u0131; t\u00fcm\u00f6r\u00fcn k\u00fc\u00e7\u00fclme oran\u0131 da belirgin \u015fekilde artt\u0131.<\/p>\n

    \n
    Bu ne anlama geliyor?<\/div>\n

    Bir hastan\u0131n t\u00fcm\u00f6r\u00fcndeki gen de\u011fi\u015fikliklerini bilmek, ona \u00f6zel ve \u00e7ok daha etkili tedavilerin se\u00e7ilmesini sa\u011fl\u0131yor. Bu, “ki\u015fiye \u00f6zel kanser tedavisi”<\/strong> anlay\u0131\u015f\u0131n\u0131n g\u00fczel bir \u00f6rne\u011fidir.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

    \n
    \n

    Ba\u011f\u0131rsak Kanseri \u00b7 <\/span>HER2 \u2014 pozitif hastalarda yeni nesil ak\u0131ll\u0131 ila\u00e7<\/h2>\n<\/div>\n
    \n

    HORIZON-CRC01 \u00e7al\u0131\u015fmas\u0131nda<\/strong>, HER2<\/em> adl\u0131 proteini ta\u015f\u0131yan ve standart tedavilere yan\u0131t vermeyen hastalarda trastuzumab rezetekan<\/strong> adl\u0131 antikor-ila\u00e7 birle\u015fimi, standart tedaviye g\u00f6re hastal\u0131\u011f\u0131n ilerlemesini anlaml\u0131 \u015fekilde geciktirdi.<\/p>\n

    \n
    Bu ne anlama geliyor?<\/strong><\/div>\n

    Ak\u0131ll\u0131 ila\u00e7lar, kemoterapiyi do\u011frudan kanser h\u00fccresinin i\u00e7ine ta\u015f\u0131yarak sa\u011fl\u0131kl\u0131 dokulara daha az zarar verir. Bu s\u0131n\u0131ftaki ila\u00e7lar giderek daha fazla kanser t\u00fcr\u00fcnde i\u015fe yar\u0131yor.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

    \n
    \n

    Akci\u011fer Kanseri – <\/span>Ameliyat sonras\u0131 n\u00fcks riskini %83 azaltt\u0131<\/h2>\n<\/div>\n
    \n

    Akci\u011fer kanserlerinin bir k\u0131sm\u0131 RET<\/em> adl\u0131 bir gen de\u011fi\u015fikli\u011fi ta\u015f\u0131r. LIBRETTO-432 \u00e7al\u0131\u015fmas\u0131nda<\/strong>, ameliyat olmu\u015f bu hastalara selperkatinib<\/strong> adl\u0131 hap verilmesi, kanserin geri d\u00f6nme veya \u00f6l\u00fcm riskini %83 oran\u0131nda<\/strong> azaltt\u0131.<\/p>\n

    \n
    Bu ne anlama geliyor?<\/strong><\/div>\n

    Erken evrede ameliyatla birlikte do\u011fru hedefe y\u00f6nelik ilac\u0131n kullan\u0131lmas\u0131, kanserin geri d\u00f6n\u00fc\u015f\u00fcn\u00fc \u00e7ok ciddi oranda \u00f6nleyebiliyor. Ayr\u0131ca nadir gen de\u011fi\u015fiklikleri ta\u015f\u0131yan akci\u011fer kanseri hastalar\u0131 i\u00e7in de yeni ve etkili hap se\u00e7enekleri sunuldu.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

    \n

    \u00a0Meme Kanseri \u2014 PIK3CA gen de\u011fi\u015fikli\u011fi ta\u015f\u0131yan hastalar i\u00e7in yeni kombinasyon<\/h2>\n
    \n

    VIKTORIA-1 \u00e7al\u0131\u015fmas\u0131<\/strong>, hormon pozitif \/ HER2 negatif ve PIK3CA<\/em> gen de\u011fi\u015fikli\u011fi ta\u015f\u0131yan, \u00f6nceki tedavide ilerleme g\u00f6stermi\u015f meme kanseri hastalar\u0131nda gedatolisib<\/strong> adl\u0131 yeni bir ilac\u0131n hormon tedavisiyle birle\u015ftirilmesini de\u011ferlendirdi ve umut verici sonu\u00e7lar elde edildi.<\/p>\n

    Ayr\u0131ca \u00fc\u00e7l\u00fc negatif meme kanserinde yeni bir ak\u0131ll\u0131 ilac\u0131n hem hastal\u0131\u011f\u0131n ilerlemesini geciktirdi\u011fi hem de ya\u015fam s\u00fcresini uzatt\u0131\u011f\u0131 bildirildi.<\/p>\n

    \n
    Bu ne anlama geliyor?<\/strong><\/div>\n

    Meme kanseri tek bir hastal\u0131k de\u011fildir; alt tiplerine g\u00f6re farkl\u0131 tedaviler giderek daha hassas bi\u00e7imde se\u00e7ilebiliyor ve se\u00e7enekler art\u0131yor.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

    \n
    \n

    Immunotherapy <\/span>\u2014 V\u00fccudun kendi savunmas\u0131n\u0131 kullanan tedaviler geni\u015fliyor<\/h2>\n<\/div>\n
    \n

    \u0130mm\u00fcnoterapi, v\u00fccudun ba\u011f\u0131\u015f\u0131kl\u0131k sistemini kanserle sava\u015fmas\u0131 i\u00e7in g\u00fc\u00e7lendiren bir tedavi yakla\u015f\u0131m\u0131d\u0131r. Bu y\u0131l \u00f6ne \u00e7\u0131kan geli\u015fmeler:<\/p>\n

      \n
    • \u0130leri evre melanomada hastan\u0131n kendi ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerinin \u00e7o\u011falt\u0131l\u0131p geri verildi\u011fi h\u00fccre tedavisinin (lifileucel<\/strong>) uzun s\u00fcreli yarar sa\u011flad\u0131\u011f\u0131 g\u00f6r\u00fcld\u00fc.<\/li>\n
    • Ba\u015f-boyun kanserlerinde ve di\u011fer baz\u0131 t\u00fcm\u00f6rlerde yeni nesil hedefli ba\u011f\u0131\u015f\u0131kl\u0131k ila\u00e7lar\u0131 (bispesifik tedaviler<\/strong>) umut verici yan\u0131tlar olu\u015fturdu.<\/li>\n
    • Ba\u011f\u0131\u015f\u0131kl\u0131k tedavisine yan\u0131t vermeyen baz\u0131 hastalar i\u00e7in yeni kombinasyonlar denendi.<\/li>\n<\/ul>\n
      \n
      Bu ne anlama geliyor?<\/strong><\/div>\n

      Ba\u011f\u0131\u015f\u0131kl\u0131k sistemini kullanan tedaviler art\u0131k sadece birka\u00e7 kanser t\u00fcr\u00fcyle s\u0131n\u0131rl\u0131 de\u011fil; giderek daha fazla hastaya ula\u015f\u0131yor ve baz\u0131 hastalarda \u00e7ok uzun s\u00fcreli kontrol sa\u011flayabiliyor.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

      \n
      \n

      Destekleyici Bak\u0131m <\/span>\u2014 D\u00fc\u015f\u00fck maliyetli, basit yakla\u015f\u0131mlar da \u00f6ne \u00e7\u0131kt\u0131<\/h2>\n<\/div>\n
      \n

      Bu y\u0131lki toplant\u0131 yaln\u0131zca yeni ila\u00e7lara de\u011fil, hastalar\u0131n ya\u015fam kalitesini art\u0131ran basit ve d\u00fc\u015f\u00fck maliyetli y\u00f6ntemlere de yer verdi. Kemoterapi \u00f6ncesi beslenme d\u00fczenlemeleri<\/strong> ve yoga<\/strong> gibi hareket temelli uygulamalar\u0131n hastalara iyi geldi\u011fine dair veriler payla\u015f\u0131ld\u0131. Ayr\u0131ca diyabet ve kilo tedavisinde kullan\u0131lan baz\u0131 ila\u00e7lar\u0131n (GLP-1 grubu<\/strong>) kanser hastalar\u0131nda olas\u0131 faydalar\u0131 tart\u0131\u015f\u0131ld\u0131.<\/p>\n

      \n
      Bu ne anlama geliyor?<\/strong><\/div>\n

      \u0130yi bir kanser bak\u0131m\u0131 sadece t\u00fcm\u00f6r\u00fc tedavi etmek de\u011fil, ayn\u0131 zamanda hastan\u0131n kendini iyi hissetmesini sa\u011flamakt\u0131r. Bazen en de\u011ferli iyile\u015ftirmeler en basit y\u00f6ntemlerle gelir.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

      \n

      K\u0131saca Ak\u0131lda Kalmas\u0131 Gerekenler<\/h3>\n
        \n
      • \u2713<\/span> Kanser tedavisi h\u0131zla ilerliyor \u2014 her y\u0131l bir\u00e7ok kanser t\u00fcr\u00fcnde yeni ve daha etkili se\u00e7enekler ortaya \u00e7\u0131k\u0131yor.<\/li>\n
      • \u2713<\/span> Ki\u015fiye \u00f6zel tedavi giderek \u00f6nem kazan\u0131yor; t\u00fcm\u00f6r\u00fcn genetik \u00f6zelliklerini bilmek, en do\u011fru ilac\u0131n se\u00e7ilmesini sa\u011fl\u0131yor.<\/li>\n
      • \u2713<\/span> “Ak\u0131ll\u0131 ila\u00e7lar” ve hedefe y\u00f6nelik haplar, klasik kemoterapiye g\u00f6re daha az yan etkiyle daha iyi sonu\u00e7lar verebiliyor.<\/li>\n
      • \u2713<\/span> Ba\u011f\u0131\u015f\u0131kl\u0131k tedavileri daha fazla hastaya ula\u015f\u0131yor.<\/li>\n
      • \u2713<\/span> Ya\u015fam kalitesi, tedavinin ayr\u0131lmaz bir par\u00e7as\u0131 olarak \u00f6ne \u00e7\u0131k\u0131yor.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n

         <\/p>\n

         <\/p>\n

         <\/p>\n

         <\/p>\n

        \n
        K\u00fc\u00e7\u00fck S\u00f6zl\u00fck<\/strong><\/div>\n
        Yaz\u0131da ge\u00e7en t\u0131bbi terimlerin sade a\u00e7\u0131klamalar\u0131<\/div>\n
        Metastaz<\/strong> Kanserin ba\u015flad\u0131\u011f\u0131 yerden v\u00fccudun ba\u015fka b\u00f6lgelerine yay\u0131lmas\u0131.<\/div>\n
        Gen \/ Mutasyon (gen de\u011fi\u015fikli\u011fi)<\/strong> Kanser h\u00fccrelerinde bulunan ve b\u00fcy\u00fcmelerine yol a\u00e7abilen de\u011fi\u015fiklikler; baz\u0131 ila\u00e7lar bu de\u011fi\u015fiklikleri \u00f6zel olarak hedef al\u0131r.<\/div>\n
        Hedefe Y\u00f6nelik Tedavi<\/strong> Kanser h\u00fccresine \u00f6zg\u00fc bir \u00f6zelli\u011fi hedef alan, sa\u011fl\u0131kl\u0131 h\u00fccrelere daha az zarar veren tedavi.<\/div>\n
        Ak\u0131ll\u0131 \u0130la\u00e7 (Antikor-ila\u00e7 birle\u015fimi)<\/strong> Kemoterapiyi do\u011frudan kanser h\u00fccresine ta\u015f\u0131yan, b\u00f6ylece etkiyi art\u0131r\u0131p yan etkiyi azaltmay\u0131 ama\u00e7layan ila\u00e7.<\/div>\n
        Immunotherapy <\/strong>V\u00fccudun kendi ba\u011f\u0131\u015f\u0131kl\u0131k sistemini kanserle sava\u015fmas\u0131 i\u00e7in g\u00fc\u00e7lendiren tedavi.<\/div>\n
        Genel Sa\u011fkal\u0131m<\/strong> Hastalar\u0131n ortalama olarak ne kadar s\u00fcre ya\u015fad\u0131\u011f\u0131n\u0131 g\u00f6steren \u00f6l\u00e7\u00fct.<\/div>\n<\/div>\n
        <\/div>\n
        <\/div>\n
        <\/div>\n
        <\/div>\n
        \n
        \n

        \u00d6nemli Not:<\/strong> Bu yaz\u0131 yaln\u0131zca genel bilgilendirme amac\u0131yla haz\u0131rlanm\u0131\u015ft\u0131r ve ki\u015fisel t\u0131bbi tavsiye yerine ge\u00e7mez. Burada bahsedilen tedavilerin bir k\u0131sm\u0131 hen\u00fcz ara\u015ft\u0131rma a\u015famas\u0131ndad\u0131r veya t\u00fcm \u00fclkelerde \/ her hasta i\u00e7in uygun olmayabilir. Her hastan\u0131n durumu kendine \u00f6zg\u00fcd\u00fcr. Tedavinizle ilgili kararlar yaln\u0131zca sizi takip eden hekiminizle birlikte verilmelidir.<\/p>\n

        Haz\u0131rlayan: Tansan Klini\u011fi<\/strong> \u00b7 Haziran 2026<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

        \u2022 Based on the 2026 ASCO Annual Meeting held in Chicago, USA \u2022 A concise summary for patients from the world's largest cancer congress Tansan Clinic June 2026 450+ scientific studies Every year in May\u2013June, cancer experts from around the world gather at the ASCO Annual Meeting. This meeting is where the most important innovations in cancer treatment are announced for the first time.<\/p>","protected":false},"author":2,"featured_media":2626,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[524],"tags":[],"class_list":["post-3495","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-haberler"],"_links":{"self":[{"href":"https:\/\/staging.tansan.com.tr\/en\/wp-json\/wp\/v2\/posts\/3495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/staging.tansan.com.tr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.tansan.com.tr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.tansan.com.tr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.tansan.com.tr\/en\/wp-json\/wp\/v2\/comments?post=3495"}],"version-history":[{"count":2,"href":"https:\/\/staging.tansan.com.tr\/en\/wp-json\/wp\/v2\/posts\/3495\/revisions"}],"predecessor-version":[{"id":3498,"href":"https:\/\/staging.tansan.com.tr\/en\/wp-json\/wp\/v2\/posts\/3495\/revisions\/3498"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/staging.tansan.com.tr\/en\/wp-json\/wp\/v2\/media\/2626"}],"wp:attachment":[{"href":"https:\/\/staging.tansan.com.tr\/en\/wp-json\/wp\/v2\/media?parent=3495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.tansan.com.tr\/en\/wp-json\/wp\/v2\/categories?post=3495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.tansan.com.tr\/en\/wp-json\/wp\/v2\/tags?post=3495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}